1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Keloids - Pipeline Review, H1 2015

Keloids - Pipeline Review, H1 2015

  • February 2015
  • -
  • Global Markets Direct
  • -
  • 55 pages

Keloids - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Keloids - Pipeline Review, H1 2015’, provides an overview of the Keloids’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keloids and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Keloids
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Keloids and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Keloids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Keloids pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Keloids
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Keloids pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Keloids - Pipeline Review, H1 2015
Table of Contents
Introduction 5
Global Markets Direct Report Coverage 5
Keloids Overview 6
Therapeutics Development 7
Pipeline Products for Keloids - Overview 7
Pipeline Products for Keloids - Comparative Analysis 8
Keloids - Therapeutics under Development by Companies 9
Keloids - Therapeutics under Investigation by Universities/Institutes 10
Keloids - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Keloids - Products under Development by Companies 13
Keloids - Products under Investigation by Universities/Institutes 14
Keloids - Companies Involved in Therapeutics Development 15
Delenex Therapeutics AG 15
RestorGenex Corporation 16
RXi Pharmaceuticals Corporation 17
Vida Therapeutics Inc. 18
Keloids - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
CIGB-128 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
CM-101 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
DLX-1008 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
koebnerisin - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
P-529 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
psoriasin - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Recombinant Protein to Inhibit Granzyme B for Cardiovascular and Dermatology Diseases - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
RXI-109 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
V-2248 - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Keloids - Recent Pipeline Updates 41
Keloids - Dormant Projects 47
Keloids - Discontinued Products 48
Keloids - Product Development Milestones 49
Featured News and Press Releases 49
Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study 49
Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 49
Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 50
Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 51
Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 51
Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program 52
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for Keloids, H1 2015 7
Number of Products under Development for Keloids - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Keloids - Pipeline by Delenex Therapeutics AG, H1 2015 15
Keloids - Pipeline by RestorGenex Corporation, H1 2015 16
Keloids - Pipeline by RXi Pharmaceuticals Corporation, H1 2015 17
Keloids - Pipeline by Vida Therapeutics Inc., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Keloids Therapeutics - Recent Pipeline Updates, H1 2015 41
Keloids - Dormant Projects, H1 2015 47
Keloids - Discontinued Products, H1 2015 48

List of Figures

Number of Products under Development for Keloids, H1 2015 7
Number of Products under Development for Keloids - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Top 10 Targets, H1 2015 20
Number of Products by Stage and Top 10 Targets, H1 2015 20
Number of Products by Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Top 10 Routes of Administration, H1 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 24
Number of Products by Top 10 Molecule Types, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 26

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Radiodermatitis, also known as radiation dermatitis, is a significant symptom caused by radiation therapy used in treating cancer as well as exposure to radiation during nuclear disasters. During cance ...

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Eczema - Market Insights, Epidemiology and Market Forecast-2023

Eczema - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Eczema - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.